Arrowhead Plozasiran Data Supports Triglyceride Reduction And Valuation Upside Potential [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Arrowhead Pharmaceuticals released two year extension data for its RNAi therapy plozasiran in patients with severe and moderate hypertriglyceridemia. The study showed sustained triglyceride reduction alongside a favorable safety profile over the long term. Results were presented at a major cardiology conference and focus on patient groups at high risk of acute pancreatitis with limited treatment options. For investors tracking NasdaqGS:ARWR, the plozasiran update arrives after a mixed share price path. The stock trades at $57.78, with a 2.6% gain over the past week, a 30 day return showing an 8.7% decline, and a year to date move of a 14.8% decline. Over one year the share price has risen by a very large amount, while the three year return stands at 127.5% and the five year return shows a 13.9% decline. This long term efficacy and safety readout provides fresh information on one of Arro
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and ExpoBusiness Wire
- SRPT Stock Surges on Promising Early Results From siRNA Programs [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals: Transition Phase With Moderate Upside Ahead [Seeking Alpha]Seeking Alpha
- Johnson & Johnson Exits 3 Biotechs but Keeps Stakes in These Rumored Acquisition Targets [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals (ARWR) had its "buy" rating reaffirmed by HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
ARWR
Earnings
- 2/5/26 - Miss
ARWR
Sec Filings
- 3/26/26 - Form SCHEDULE
- 3/20/26 - Form 8-K
- 3/9/26 - Form 4
- ARWR's page on the SEC website